Quadcap Wealth Management’s Viking Therapeutics VKTX Stock Holding History

Quadcap Wealth Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$225K	Buy	+5,758	New	+$186K	0.02%	383
2025 Q4	–	Sell	-8,388	Closed	-$220K	–	422
2025 Q3	$220K	Sell	8,388 -2,150	-20%	-$64.1K	0.03%	370
2025 Q2	$279K	Buy	10,538 +1,347	+15%	+$35.5K	0.04%	327
2025 Q1	$222K	Buy	9,191 +170	+2%	+$5.37K	0.03%	348
2024 Q4	$363K	Sell	9,021 -907	-9%	-$51.7K	0.05%	283
2024 Q3	$629K	Sell	9,928 -21	-0.2%	-$1.23K	0.1%	213
2024 Q2	$527K	Buy	9,949 +4,398	+79%	+$288K	0.1%	237
2024 Q1	$455K	Buy	+5,551	New	+$247K	0.1%	223

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Quadcap Wealth Management's VKTX Position: Q2 2026 in Review

Quadcap Wealth Management opened a new position in Viking Therapeutics (VKTX) in Q2 2026: 5,758 shares worth $225K. The stake represents 0.02% of the portfolio and ranks #383 among its holdings. This is a return to the name: Quadcap Wealth Management previously reported a position in VKTX as recently as Q3 2025.

Quadcap Wealth Management first reported a position in VKTX in Q1 2024 and has held it in 8 quarters since. The position peaked at $629K in Q3 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

Quadcap Wealth Management held 5,758 shares of Viking Therapeutics worth $225K as of Q2 2026.
Viking Therapeutics was a new Quadcap Wealth Management position in Q2 2026.
Viking Therapeutics made up 0.02% of Quadcap Wealth Management's portfolio in Q2 2026, its #383 holding.
Quadcap Wealth Management first reported a position in Viking Therapeutics in Q1 2024 and has held it in 8 quarters since.
Quadcap Wealth Management's Viking Therapeutics position peaked at $629K in Q3 2024.
436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Quadcap Wealth Management's 13F filing for Q2 2026, filed 31 Jul 2026.